1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Voyageur and Bayer Sign $2.35M Collaboration to Advance U.S. Iodine Production for Contrast Media

24 Feb 2026
Admin
News Article

Voyageur and Bayer Sign $2.35M Collaboration to Advance U.S. Iodine Production for Contrast Media

Voyageur Pharmaceuticals Ltd. has signed a collaboration and funding agreement with Bayer, securing milestone-based support of up to USD $2.35 million to evaluate potential iodine production for use in contrast media drugs.

The agreement, effective February 22, 2026, builds on a prior letter of intent signed in December 2024 and supports Voyageur’s ambition to become the first domestic producer of iodine contrast media in the United States.

Structure of the Funding Agreement

The collaboration is structured around a feasibility study for a proposed iodine extraction plant in Oklahoma.

Milestone payments include:

$350,000 upon execution of the agreement
$1,000,000 upon commencement of the feasibility study
$1,000,000 upon completion of the feasibility study

In exchange, Bayer receives exclusivity to negotiate a potential offtake agreement for iodine produced from the project.

All intellectual property developed under the project will remain exclusively owned by Voyageur.

The agreement will terminate upon:

A decision not to commence the feasibility study
Execution of a definitive offtake agreement
Expiry of the exclusivity period

Potential Second Phase: Offtake-Linked Financing

If the feasibility study is successful, the companies may move into a second phase.

Under this potential structure:

Bayer would provide capital financing tied to iodine offtake.
Voyageur would operate and manage the production project.

The arrangement could provide non-dilutive financing for plant construction.

Technical Progress to Date

Voyageur has:

Completed initial lab bench testing
Begun work on a small transportable field unit
Targeted completion of the Bayer project feasibility study later this year

In parallel, the company is advancing a separate feasibility study for its broader radiology drug production project.

Building a Vertically Integrated Contrast Media Platform

Voyageur’s long-term strategy centers on vertical integration across the contrast media value chain.

Key assets include:

100% ownership of the Frances Creek barite project in British Columbia
Planned iodine production from the Anadarko Basin in the U.S.
Development of pharmaceutical-grade barium and iodine active pharmaceutical ingredients (APIs)

The company aims to control raw material sourcing through final drug manufacturing — a model it describes as “From the Earth to the Bottle.”

Market Opportunity

The global contrast media market was valued at $6.77 billion in 2024 and is projected to reach $13.86 billion by 2033, growing at a CAGR of 8.3%.

North America accounts for approximately 39% of global iodine contrast media demand, reflecting high diagnostic imaging volumes.

Voyageur believes domestic production could strengthen supply chain resilience in North America’s healthcare system.

Strategic Context

The agreement follows Voyageur’s January 2026 acquisition of iodine-related intellectual property from Dr. Brian Mueller, positioning the company within the iodine supply chain.

If both feasibility studies are successful, Voyageur anticipates pursuing capital expenditure financing to build a radiology drug manufacturing facility — potentially becoming a domestic producer of both barium and iodine contrast media.

What Comes Next?

Over the coming months, progress will hinge on:

Completion of feasibility studies
Technical validation of iodine extraction
Negotiation of a potential offtake agreement
Securing project-level financing

For Bayer, the collaboration offers early positioning within a potential U.S.-based iodine supply source. For Voyageur, it represents a critical step toward vertical integration in a growing global contrast media market.